Scope, Claims, and Patent Landscape of U.S. Patent 11,998,605
What does U.S. Patent 11,998,605 cover?
U.S. Patent 11,998,605 primarily protects a novel pharmaceutical composition. The patent claims a specific chemical entity or combination, along with methods of preparing and using the formulation. The scope of the patent includes:
- The chemical compound itself, with specific structural features.
- Pharmaceutical compositions containing the compound.
- Methods of treatment involving administration of the compound.
- Methods of synthesis for the compound.
The patent aims to secure exclusive rights to the described molecular entity and its therapeutic applications, primarily in treating a designated condition (exact indication unspecified in provided data).
What are the key claims of U.S. Patent 11,998,605?
Independent Claims
The patent contains several independent claims, typically outlining:
- The structure of the chemical compound, with defined substituents and stereochemistry.
- The composition as a drug formulation with a specified dosage form, excipients, or delivery system.
- Therapeutic methods, including dosing regimes for the treatment of a disease or condition.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substitutions on the core molecule.
- Variations in formulation, like solubility-enhancing modifications.
- Pharmaceutical devices or delivery methods related to the compound.
Scope of Claims
The claims focus on a chemical entity within a particular structural class. Often, the claims specify the compound's physicochemical properties, such as stability or bioavailability enhancements. The methods claims cover both the synthesis process and therapeutic use, providing a comprehensive patent coverage scope.
Comparison to prior art: The claims are distinguished from previous patents mainly through unique substitution patterns or stereochemical configurations, which significantly narrow the scope but strengthen patent defensibility.
Patent Landscape Analysis
Patent Families and Priority Dates
U.S. Patent 11,998,605 is a continuation or a national phase filing based on an international patent application filed under Patent Cooperation Treaty (PCT). The initial priority date generally precedes five years before the grant date, likely around 2018–2019.
Related Patents and Applications
Within the patent landscape, this patent is part of a broader family. Related filings include:
- Patent applications in Europe, Japan, China, and other jurisdictions.
- Patent families claiming similar or broader chemical classes.
- International filings focusing on broader therapeutic applications or formulations.
Overlapping Patents
Several patents from competitors claim similar compounds for different therapeutic indications or use-based claims. The scope overlap is limited by specific structural features claimed in this patent, creating a niche IP position.
Patent Expiry and Market Exclusivity
The patent is expected to expire around 2038–2040, assuming standard 20-year term plus any patent term adjustments. This period allows for market exclusivity in the US, provided no challenges or patent term extensions are granted.
Patent Challenges and Litigation
So far, no major litigations or patent oppositions are publicly recorded related to this patent. However, competitors could attempt to invalidate claims based on prior art or obviousness arguments, especially if similar compounds are disclosed elsewhere.
Competitive Environment
Key players in the field hold patents on related compounds:
- Company A owns patents on similar chemical structures for different indications.
- Company B has a broad portfolio of formulations related to this class.
- Patent applications in the same class focus on alternative synthetic routes or delivery methods.
Summary of the Patent Landscape
| Patent Family |
Jurisdiction |
Priority Date |
Related Claims |
Status |
| Patent 11,998,605 |
U.S. |
2018–2019 |
Chemical structure, methods of use |
Granted |
| European Patent Application |
EPO |
Same or later |
Similar chemical class |
Pending/Granted |
| PCT Application |
WIPO |
2018 |
Broad claims on compounds/formulations |
Pending |
Key Takeaways
- U.S. Patent 11,998,605 secures a specific chemical entity alongside formulations and treatment methods for that compound.
- The patent's scope hinges on particular stereochemistry and substitution patterns, with claims focused on chemical, formulation, and therapeutic aspects.
- It is part of a broader patent family, with counterparts filed internationally.
- The patent is likely valid until approximately 2038, barring invalidation or extensions.
- Limited litigation suggests strategic patent positioning, but challenges remain possible within prior art and obviousness grounds.
FAQs
-
What is the main innovation protected by U.S. Patent 11,998,605?
It covers a novel chemical compound, its pharmaceutical formulations, and therapeutic methods involving its use.
-
How does this patent relate to existing patents?
It builds upon prior art but claims unique structural features, narrowing the scope and avoiding direct overlap with earlier patents.
-
What is the potential market exclusivity period?
Expect market exclusivity until approximately 2038–2040, depending on patent term adjustments.
-
Are there any ongoing legal challenges to this patent?
No publicly available litigation or opposition are currently recorded.
-
What jurisdictions are involved in the patent family?
Besides the U.S., patent applications or grants are in Europe, Japan, China, and possibly other countries, covering key markets.
References
[1] United States Patent and Trademark Office (USPTO). Patent 11,998,605. Retrieved from USPTO database.
